DNA Methylation for Diagnosic and Prognostic Determination in Prostate Cancer
Abstract (Set) Prostate cancer is the most commonly diagnosed cancer affecting men in the United States. Biochemical (PSA) recurrence of prostate cancer following radical prostatectomy remains a major problem. Better biomarkers are needed to identify high and low-risk patients. DNA methylation of promoter regions leads to gene silencing in many cancers. Scientists at Johns Hopkins University have discovered the methylation profile of two genes which are independently associated with an increased risk of biochemical recurrence in patients who have undergone radical prostatectomies. Description (Set) Proposed Use (Set) This invention is for diagnostic and prognostic biological markers for prostate cancer recurrence.
Type of Offer:
« More Diagnostic Patents